paclitaxel has been researched along with Melanoma in 255 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.39) | 18.7374 |
| 1990's | 29 (11.37) | 18.2507 |
| 2000's | 58 (22.75) | 29.6817 |
| 2010's | 123 (48.24) | 24.3611 |
| 2020's | 44 (17.25) | 2.80 |
| Authors | Studies |
|---|---|
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Baasner, S; Beckers, T; Böhmer, FD; Burger, AM; Bürgermeister, J; Fiebig, HH; Frieser, M; Hockemeyer, J; Hufsky, H; Lyssenko, A; Mahboobi, S; Paper, DH; Pongratz, H | 1 |
| Chai, H; Cordell, GA; Farnsworth, NR; Hollingshead, MG; Kardono, LB; Kinghorn, AD; Lantvit, D; Lee, IS; Mayo, JG; Mi, Q; Ngassapa, O; Peraza-Sánchez, S; Pezzuto, JM; Reyes-Lim, E; Riswan, S; Zhao, W | 1 |
| Ayral-Kaloustian, S; Beyer, C; Discafani, C; Greenberger, L; Loganzo, F; Niu, C; Smith, D; Zask, A | 1 |
| Ahn, S; Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, J | 1 |
| Cichewicz, RH; Du, L; King, JB; Mooberry, SL; Robles, AJ | 1 |
| Arnst, KE; Banerjee, S; Deng, S; Kumar, G; Li, GB; Li, W; Miller, DD; Wang, Y; White, SW; Yang, J; Yang, L | 1 |
| Arnst, KE; Chen, ZS; Lei, ZN; Li, W; Ma, D; Miller, DD; Wang, Q; Xue, Y | 1 |
| Arnst, KE; Chen, H; Kumar, G; Li, W; Ma, D; Miller, DD; Wang, Q; Wang, Y; White, SW; Wu, Z; Yang, J | 1 |
| Gao, R; Li, N; Li, X; Ma, L; Mu, L; Song, W; Sun, Y; Tang, Z; Wang, N; Wang, R; Wei, M; Yang, C; Yang, G; Yu, X; Zhang, K; Zhang, Y; Zheng, N | 1 |
| Hiura, A; Maeda, T; Nakagawa, T; Toyoshima, R; Uehara, J; Yoshino, K | 1 |
| Bēma, D; Bērziņš, J; Buiķis, I; Freivalds, T; Harju, L; Miķelsone, I; Patetko, L; Simsone, Z | 1 |
| Alimoradi, H; Baird, SK; Barzegar-Fallah, A; Dunlop, JL; Torbati, E | 1 |
| Ewert, KK; Fisher, WS; Roberts, L; Safinya, CR; Tchounwou, C; Wei, S | 1 |
| Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X | 1 |
| Ghanadian, M; Lanzotti, V; Mehdifar, P; Mirian, M; Yazdiniapour, Z; Zolfaghari, B | 1 |
| Hu, Y; Ji, Z; Li, M; Wang, H; Xu, B; Xu, J; Yang, Y | 1 |
| Duan, X; Gu, Z; Li, A; Lou, X; Pan, L; Qin, Z; Wan, J; Wang, F; Wang, M; Yao, X; Zhang, L; Zhu, L | 1 |
| An, X; Chen, S; Dong, S; Guo, C; Li, X; Li, Y; Liu, C; Shen, N; Song, M; Zhang, W | 1 |
| Akbari, V; Emami, J; Hejazi, E; Lavasanifar, A; Minaiyan, M; Rezazadeh, M | 1 |
| Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y | 1 |
| Dehdari Vais, R; Perota, G; Sattarahmady, N; Zahraie, N | 1 |
| Feng, N; Guo, J; He, Y; He, Z; Hou, X; Hu, H; Jing, Q; Li, Y; Li, Z; Ruan, S; Wang, Z; Wu, T; Xia, Q; Zhang, B; Zhang, Y | 1 |
| Bariwal, J; Bhattarai, RS; Deng, S; Hao, C; Kumar, V; Li, W; Mahato, RI | 1 |
| Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Lan, S; Wu, D; Zhang, Y | 1 |
| Adrianzen, L; Chiu, YM; Keck, M; Lodhi, N; Nagpal, P; Parvez, Z; Sarojini, S; Suh, KS | 1 |
| Cadoná, FC; D'Ávila, CMDS; Krause, LMF; Mello, GH; Viana, AR | 1 |
| Banerjee, R; Jinka, S; Mondal, SK; Shankar, G; Srinivas, R | 1 |
| Chan, TH; Chow, LMC; Kan, JWY; Liu, Z; Su, X; Wong, ILK; Yan, CSW | 1 |
| Banerjee, S; Chen, H; Deng, S; Hartman, KL; Li, W; Meibohm, B; Miller, DD; Parmar, K; Pochampally, S; Wang, Y; White, SW; Wu, Z; Yun, MK | 1 |
| Guan, E; Hu, Y; Ji, Z; Lin, B; Wang, H; Zhou, M | 1 |
| Dai, J; Fu, S; Li, J; Liu, Y; Lu, Y; Ma, W; Shi, H; Wen, Q; Zhao, L; Zhou, P | 1 |
| Ageev, E; Antuganov, D; Karpov, TE; Maistrenko, DN; Muslimov, AR; Peltek, OO; Petrov, A; Postovalova, A; Rogova, A; Stanzhevsky, AA; Timin, AS; Zuev, D; Zyuzin, MV | 1 |
| Cho, H; Haque, TN; Rahman, S; Saraswat, AL; Sugandhi, VV; Xin, X | 1 |
| Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Adlsadabad, SY; Pourbadiei, B; Pourjavadi, A; Rahbariasr, N | 1 |
| Ambriović-Ristov, A; Coopmans, K; Humphries, JD; Humphries, MJ; Lončarić, M; Majhen, D; Rac-Justament, A; Stojanović, N | 1 |
| Dülgar, Ö; Elleson, KM; Markowitz, J; Saha, A | 1 |
| Edwards, CRW; Goff, PS; Gorelkin, PV; Korchev, Y; Sviderskaya, EV; Woodcock, E; Zhang, Y | 1 |
| Jin, B; Kim, SY; Lee, WW; Li, Q; Nam, A; Park, HJ; Ryu, MO; Son, MH; Song, WJ; Yang, JI; Youn, HY | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Anderson, DM; Erickson, LA; Ernstoff, M; Javed, A; Markovic, SN; Reid, JM; Suman, VJ; Wall, DJ | 1 |
| Gao, Z; Si, X; Xu, F; Zheng, Y | 1 |
| Chen, X; Fu, Y; Gong, T; Hu, Y; Wang, M; Yu, R; Zhang, ZR | 1 |
| Gong, T; He, Q; Huang, S; Lin, Q; Liu, W; Sun, X; Wang, L; Xiao, L; Zhang, L; Zhang, Y; Zhang, Z | 1 |
| Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X | 1 |
| Gebhardt, C; Gries, M; Holland-Letz, T; Mun, DH; Reinhard, R; Simon, SCS; Umansky, V; Utikal, J; Weber, R | 1 |
| Bai, X; Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X; Yao, H; Zhou, L | 1 |
| Lee, Y; Park, D | 1 |
| Berges, A; Cho, H; Dean, E; Hong, JY; Irurzun-Arana, I; Kang, WK; Kim, KM; Kim, ST; Kozarewa, I; Lee, J; Lim, HY; Loembé, AB; Mortimer, P; Park, JO; Park, SH; Park, YS; Pierce, AJ; Smith, C; Smith, SA; Willis, S | 1 |
| Ashworth, A | 1 |
| Dingv, Y; Huang, FX; Jiang, H; Li, DD; Li, JJ; Liu, X; Wang, JH; Wen, XZ; Zhang, XS; Zhao, JJ | 1 |
| Acri, T; Alhaj-Suliman, SO; Ebeid, K; Mekkawy, AI; Naguib, YW; Salem, AK; Wafa, EI | 1 |
| Lee, BJ; Tran, PH; Tran, TT; Yoon, TJ | 1 |
| Jeoung, D; Kim, Y; Yeon, M | 1 |
| Carvalho, VFM; Costa-Lotufo, LV; de Lemos, DP; Giacone, DV; Lopes, LB; Maria-Engler, SS; Migotto, A; Zanoni, TB | 1 |
| Bauer-Pohl, V; Bennett, K; Beqiri, M; Chen, G; Choi, H; Czerniecki, BJ; Damle, M; Davies, MA; Dunagin, M; Ellingsworth, C; Flaherty, K; Frederick, DT; Fukunaga-Kalabis, M; Garg, K; Gavin, BJ; Grinman, L; Griss, J; Gross, L; Hafner, C; Hards, R; Herlyn, D; Herlyn, M; Hristova, D; Hudgens, C; Jalili, A; Karanikas, G; Koller, J; Krepler, C; Lang, R; Liu, Q; Long, GV; Maurer, M; Mayerhöfer, M; Perego, M; Raj, A; Rappersberger, K; Schaider, H; Scholler, N; Schuchter, L; Scolyer, RA; Somasundaram, R; Tetzlaff, M; Tian, T; Wagner, C; Wagner, SN; Wargo, J; Watson, I; Wei, Z; Weihsengruber, F; Wu, L; Xu, X; Zhang, G; Zhang, J | 1 |
| Allred, JB; Bryce, AH; Dronca, RS; Erickson, LA; Joseph, RW; Katipamula, R; King, DM; Kottschade, LA; Leitch, JM; Markovic, SN; McWilliams, RR; Rumilla, KM; Slostad, JA | 1 |
| Chantharasamee, J; Ithimakin, S; Singsuksawat, E; Sootichote, R; Thuwajit, C; Thuwajit, P; Warnnissorn, M; Yenchitsomanus, PT | 1 |
| Dukhanin, AS; Dukhanina, EA; Georgieva, SG; Luk'yanova, TI | 1 |
| Adjei, AA; Bindeman, WE; Cao, S; Chanana, P; Dong, H; Dronca, RS; Harrington, SM; Jang, JS; Jen, J; Li, Y; Liu, X; Mansfield, AS; Markovic, SN; Park, SS; Yan, Y | 1 |
| Han, T; Hao, J; Liu, J; Tang, H; Wang, M; Wang, X; Wang, Y; Zhuang, Q | 1 |
| El-Masry, M; Fruehauf, JP; Jakowatz, JG; Osann, K; Parmakhtiar, B; Yamamoto, M | 1 |
| Berić Jozić, G; Lukić, B; Marijanović, I; Miletić, D; Puljić Ćuk, A; Tica Sedlar, I; Tomić, K | 1 |
| Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA | 1 |
| He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z | 1 |
| Eshita, Y; Ji, RC; Kobayashi, T; Kubota, N; Mizuno, M; Onishi, M; Onishi, Y; Yoshida, J | 1 |
| He, B; Jiang, T; Li, T; Ma, Y; Mo, R; Shen, S; Wang, T | 1 |
| Forschner, A; Garbe, C; Gutmann, V; Kosnopfel, C; Makino, E; Niessner, H; Schittek, B; Sinnberg, T | 1 |
| Corrie, P; Danson, S; Goff, M; Love, SB; Marshall, E; Mauch, C; Middleton, MR; Mohammed, SB; Plummer, E; Schadendorf, D; Scudder, C; Urbonas, V; Wheater, M; Zimmer, L | 1 |
| Han, B; Sun, B; Wang, YB | 1 |
| Hata, H; Hiura, A; Kato, M; Maeda, T; Nagai, K; Oaku, S; Yoshino, K | 1 |
| Specenier, P | 1 |
| Kirkwood, JM; Massa, RC | 1 |
| Chan, J; Corrie, P; di Pietro, M; Fitzgerald, RC; Januszewicz, W; Liu, H | 1 |
| Chowdhury, MR; Goto, M; Kamiya, N; Moniruzzaman, M; Moshikur, RM; Tahara, Y; Wakabayashi, R | 1 |
| Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Ma, M; Sheng, X; Si, L; Tang, H; Xu, L; Xu, T; Yan, J; Yang, L; Yu, H; Yu, S | 1 |
| Curran, C; Liang, G; Mehaidli, A; Nguyen, C; Pandey, S; Parashar, K; Pignanelli, C; Sood, S; Vegh, C; Wang, Y; Wu, J | 1 |
| al-Ramadi, BK; Bashir, G; El-Kharrag, R; El-Taji, H; Fernandez-Cabezudo, MJ; George, JA; Torab, F | 1 |
| Chang, W; Choi, MK; Hong, JY; Jung, HA; Kim, S; Kim, YS; Lee, J; Lee, SJ; Maeng, CH; Park, S | 1 |
| Cliby, WA; Janco, JM; Markovic, SN; Weaver, AL | 1 |
| Akasaka, T; Inoue, T; Kasai, S; Maesawa, C; Masuda, T; Shibazaki, M; Takahashi, K; Watanabe, A; Yasuhira, S | 1 |
| Liu, YP; Luo, YH; Song, JG; Sun, P; Xu, HM; Zhang, L; Zhang, XJ | 1 |
| Arrowsmith, ER; Hainsworth, JD; Hauke, RJ; Infante, JR; Rubin, MS; Shih, KC | 1 |
| Carrà, A; D'Incalci, M; Davoli, E; Giavazzi, R; Morosi, L; Pretto, F; Spinelli, P; Zucchetti, M | 1 |
| Costa, VM; Diniz, C; Fresco, P; Soares, AS | 3 |
| El-Khattouti, A; Gomez, CR; Haïkel, Y; Hassan, M; Megahed, M; Selimovic, D | 1 |
| Deng, R; Dong, L; Liang, R; Liu, S; Sullivan, M; Tao, J; Wang, J; Wang, K; Wu, M; Wu, X; Yang, X; Zhu, J | 1 |
| Glowala-Kosinska, M; Gogler-Piglowska, A; Toma, A; Vydra, N; Widlak, W | 1 |
| Ashida, A; Okuyama, R; Sato, Y; Uhara, H | 1 |
| Amaravadi, RK; Anderson, AR; Fedorenko, IV; Gibney, GT; Kim, E; Kudchadkar, RR; Maria-Engler, SS; Massaro, RR; Messina, JL; Rebecca, VW; Smalley, KS; Sondak, VK | 1 |
| Amonkar, MM; Casey, M; Demidov, LV; Dummer, R; Garbe, C; Grotzinger, K; Hassel, JC; Lefeuvre-Plesse, C; Milhem, M; Mohr, P; Patel, K; Robert, C; Rutkowski, P; Rutten, A; Schadendorf, D; Sherman, L; Steven, N; Trefzer, U; Ullenhag, G; Wolter, P; Wu, FS | 1 |
| Koon, HB; Megahed, AI | 1 |
| Arance, A; Conti, I; Garbe, C; Grob, JJ; Hahka-Kemppinen, M; Hamid, O; Hauschild, A; Hutson, TE; Ilaria, R; Kaiser, C; Lee, J; Lorigan, P; Maio, M; Mohr, P; Turner, PK; Wolter, P | 1 |
| D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F | 1 |
| Kato, J; Namikawa, K; Tanaka, R; Tsutsumida, A; Yamazaki, N | 1 |
| Du, R; Song, P; Song, WD; Tang, YQ; Wang, C; Zhang, Q; Zhang, WQ; Zhang, X; Zhao, Y; Zhong, T | 1 |
| Azzarito, T; Cesolini, A; Fais, S; Venturi, G | 1 |
| Amemiya, H; Ando, N; Harada, K; Hosomura, N; Inozume, T; Kawamura, T; Matsuzawa, M; Shibagaki, N; Shimada, S | 1 |
| Ciria, C; Collins, L; Corrie, P; Coupe, N; Gore, M; Gupta, A; Hategan, M; Larkin, J; Love, S; Middleton, MR; Suter, S; Wise, A | 1 |
| Boasberg, P; Cruickshank, S; Hamid, O; Mesko, S; O'Day, S; Spitler, LE; Weber, RW | 1 |
| Azzariti, A; Cocco, T; Ferretta, A; Guida, G; Guida, M; Guida, S; Iacobazzi, RM; Maida, I; Porcelli, L; Quatrale, AE; Sidella, L; Stolfa, DA; Strippoli, S; Tommasi, S | 1 |
| Kato, M; Kumasaka, MY; Nghia, PT; Thang, ND; Yajima, I | 1 |
| Ascierto, PA; Bryce, A; Chmielowski, B; D'Angelo, SP; Grob, JJ; Grossmann, KF; Gutzmer, R; Hassel, JC; Hodi, FS; Hoeller, C; Horak, C; Khushalani, NI; Krackhardt, AM; Lambert, A; Lao, CD; Larkin, J; Linette, GP; Lorigan, P; Maio, M; Miller, WH; Minor, D; Mohr, P; Neyns, B; Svane, IM; Sznol, M; Thomas, L; Weber, JS; Yang, AS | 1 |
| Aksoy, A; Arpaci, E; Berk, V; Gumusay, O; Ozaslan, E | 1 |
| Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V | 1 |
| Algazi, AP; Bastian, BC; Behr, S; Cha, E; Chong, K; Coakley, F; Cortez, B; Daud, AI; Hwang, J; Liu, S; McCalmont, T; Ortiz-Urda, SM; Pampaloni, MH; Quiroz, A | 1 |
| Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM | 1 |
| Gong, T; Shen, H; Shi, S; Sun, X; Zhang, Z | 1 |
| Jang, GH; Kim, NY; Lee, M | 1 |
| Chen, H; Li, Q; Peng, L; Xiong, W | 1 |
| Ahmed, W; Elhissi, AM; Fan, M; Phoenix, DA; Sun, X; Wan, KW; Xu, H; Zhang, Z | 1 |
| Gao, H; He, Q; Qiu, Y; Yuan, M; Zhang, L | 1 |
| Jasti, B; Li, X; Saraf, P; Wrischnik, L | 1 |
| Azzariti, A; Guida, G; Guida, M; Porcelli, L; Tommasi, S | 1 |
| Ding, Y; Guo, YQ; Li, DD; Li, JJ; Peng, RQ; Wen, XZ; Zhang, X; Zhang, XS | 1 |
| D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F | 1 |
| Carlino, MS; Long, GV | 1 |
| Agarwala, SS; Bhatia, S; Brachmann, C; Brown, MP; Clawson, A; Conry, R; Del Vecchio, M; Elias, I; Ernst, S; Grob, JJ; Gutzmer, R; Hauschild, A; Haydon, A; Hersh, EM; Homsi, J; Karnoub, M; Kefford, R; Kendra, K; Li, M; Loquai, C; Renschler, MF; Robert, C; Testori, A | 1 |
| Leon-Ferre, RA; Markovic, SN | 1 |
| Kaluđerović, GN; Krajnović, T; Maksimović-Ivanić, D; Mijatović, S; Wessjohann, LA | 1 |
| Casafont, Í; Fanarraga, ML; Fernández, F; García-Hevia, L; González, J; Valiente, R; Villegas, JC | 1 |
| Cheng, PF; Dummer, R; Goldinger, SM; Guenova, E; Jaberg-Bentele, N; Kunz, M; Levesque, MP; Mangana, J; Nagel, HW; Nägeli, M; Thurneysen, S; Ziegler, M | 1 |
| Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR | 1 |
| Duncan, B; Hou, S; Jeong, Y; Jiang, Y; Kim, C; Kim, CS; Kim, ST; Park, MH; Rotello, VM; Saha, K; Tang, R; Yan, B; Yeh, YC | 1 |
| Ayub, M; Brady, G; Dhomen, N; Dive, C; Fusi, A; Garner, G; Girotti, MR; Gremel, G; Lee, RJ; Lorigan, P; Mandal, AK; Marais, R; Rothwell, DG; Valpione, S; Wallace, A; Wood, S | 1 |
| Jia, DD; Jin, G; Li, T; Wu, H; Xia, LM; Zheng, AW | 1 |
| Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W | 1 |
| He, Q; Qiu, Y; Ruan, S; Shi, K; Tai, X; Xiang, B; Yang, Y; Zhang, Z | 1 |
| Maesawa, C; Nishiya, M; Shibazaki, M; Yasuhira, S | 1 |
| Huong, PT; Minh, NV; Thang, ND | 1 |
| Chen, Q; Flowers, CR; Goldstein, DA; Kohn, CG; Montero, AJ; Zeichner, SB | 1 |
| Amagai, M; Fujita, T; Fukuda, K; Funakoshi, T; Kawakami, Y; Mori, M; Nakamura, Y; Okamoto, M; Sakurai, T; Taguchi, J; Tanese, K; Tanikawa, A | 1 |
| Hu, J; Huang, Y; Huang, Z; Liu, H; Peng, B; Su, Y; Xie, N | 1 |
| Basu, R; Baumgaertel, N; Kopchick, JJ; Wu, S | 1 |
| Chopitea, A; Díaz-Lagares, A; Espinós, J; González, A; González-Cao, M; Martín-Algarra, S; Nieto, Y; Ponz, M; Redondo, P; Viteri, S | 1 |
| Ghaidi, F; Joshi, B; Kojic, LD; Nabi, IR; Nedev, H; Saragovi, HU; Wiseman, SM | 1 |
| Brindley, DN; Gaetano, C; Goping, IS; Samadi, N | 1 |
| Amatruda, T; Constantinou, CL; Egner, JR; Fitch, TR; Jilani, SZ; Kottschade, LA; Markovic, SN; Morton, RF; Perez, DG; Suman, VJ | 1 |
| Akasaka, K; Akasaka, T; Maeda, F; Maesawa, C; Masuda, T; Shibazaki, M; Takahashi, K | 1 |
| Gude, RP; Murthy, RS; Rajyaguru, TH; Shenoy, VS | 1 |
| Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C | 1 |
| Domb, AJ; Shikanov, A; Shikanov, S; Vaisman, B | 1 |
| Agarwala, SS; Daud, A; Eggermont, A; Garbe, C; Gille, J; Gonzalez, R; Grabbe, S; Hauschild, A; Hersey, P; Hogg, D; Keilholz, U; Kirkwood, JM; O'Day, S; Patel, K; Peschel, C; Robert, C; Schadendorf, D; Trefzer, U; White, JM; Xia, C | 1 |
| Adams, VR; Cho, MJ; Dong, X; Liu, Y; Mattingly, CA; Mumper, RJ; Tseng, MT | 1 |
| Berneburg, M; Clasen, S; Eigentler, T; Forschner, A; Garbe, C; Guenova, E; Knaudt, B; Leiter, U; Meier, F; Zielinski, C | 1 |
| D'Agnano, I; Felsani, A; Florenzano, F; Gatti, G; Maresca, G; Natoli, M; Nicolin, A | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| Alexandrescu, DT; Dasanu, CA; Ichim, TE; Kabigting, F | 1 |
| Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE | 2 |
| Anderson, C; Gonzalez, R; Haddad, J; Hutchins, L; Jacobson, E; Kong, S; Lawson, D; O'Day, S; Weber, R; Williams, A | 1 |
| Clawson, AA; Gonzalez, R; Gordon, MS; Hersh, EM; O'Day, SJ; Ribas, A; Samlowski, WE; Shechter, DE | 1 |
| Atkins, MB; Bhatt, RS; Heymach, JV; McDermott, D; Merchan, J; Parker, R; Seery, V; Sukhatme, VP; Wu, HK; Zhang, L | 1 |
| Li, Z; Wang, J; Yang, T; Yin, J; Zhang, Q; Zhang, X | 1 |
| Balkissoon, J; Boxall, J; Chaplin, DJ; Ganesan, TS; Gaya, A; Nathan, PD; Poupard, L; Rustin, GJ; Shreeves, G; Stratford, MR; Wang, D; Zweifel, M | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL | 1 |
| Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF | 1 |
| Berneburg, M; Eigentler, TK; Garbe, C; Ikenberg, K; Keim, U; Leiter, U; Pflugfelder, A; Weide, B | 1 |
| Bröcker, EB; Klink, T; Meyer, KM; Ugurel, S | 1 |
| Amatruda, T; Behrens, R; Fitch, TR; Jaslowski, AJ; Kottschade, LA; Markovic, SN; Mattar, BI; McWilliams, RR; Nikcevich, DA; Suman, VJ | 1 |
| Sevko, A; Umansky, V | 1 |
| Carson, WE; Chen, D; Cheverton, P; Fruehauf, JP; Kim, KB; Linette, GP; Markovic, SN; McDermott, DF; Nguyen, H; O'Day, SJ; Peterson, AC; Sosman, JA; Weber, JS | 1 |
| Asensi, M; Brown, BD; Cerdá, M; Estrela, JM; Mena, S; Obrador, E; Ortega, A; Petschen, I; Priego, S; Rodriguez, ML | 1 |
| Bhaskar, S; Chandra, S; Mamilapally, S; Roy, A; Upadhyay, P | 1 |
| Juergens, R; Levine, MN | 1 |
| Barlesi, F; Bondarenko, I; Chacko, R; Cuillerot, JM; Lu, H; Luft, A; Lynch, TJ; Neal, J; Reck, M; Sebastian, M; Serwatowski, P | 1 |
| Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M | 1 |
| Dong, J; Guan, M; Wong, PF; Wu, J; Xu, J; Yu, H | 1 |
| Jasti, B; Javali, NM; Li, X; Raj, A; Saraf, P | 1 |
| Kim, KB | 1 |
| Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Bertin, R; Bolcato, J; Caparrotta, L; Chen, Z; Froldi, G; Montopoli, M | 1 |
| Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS | 1 |
| Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F | 1 |
| Beckhove, P; Kato, M; Michels, T; Sevko, A; Shurin, GV; Shurin, MR; Umansky, L; Umansky, V; Vrohlings, M | 1 |
| Bahcall, S; Chiarion-Sileni, V; Collichio, F; Eggermont, AM; Friedlander, P; Garbe, C; Grob, JJ; Guo, W; Hauschild, A; Kefford, R; Lufkin, J; Mackiewicz, J; Mortier, L; O'Day, SJ; Robert, C; Schachter, J; Testori, A; Ugurel, S; Vukovic, V | 1 |
| Cappugi, P; Coronnello, M; Giannotti, B; Mini, E; Pimpinelli, N; Prignano, F | 1 |
| Li, Y; McClay, EF | 1 |
| Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Dicker, AP; Grant, DS; Williams, TL; Zahaczewsky, M | 1 |
| Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E | 1 |
| Entin, I; Keisari, Y; Korenstein, R; Plotnikov, A | 1 |
| Bergstralh, DT; Clements, C; MacKeigan, JP; Taxman, DJ; Ting, JP | 1 |
| Baraldi, PG; Borea, PA; Capitani, S; Gessi, S; Leung, E; Merighi, S; Mirandola, P; Tabrizi, MA; Varani, K | 1 |
| Becker, JC; Figl, R; Hauschild, A; Hofmann, U; Keller, I; Schadendorf, D; Trefzer, U; Zimpfer-Rechner, C | 1 |
| Bedikian, AY; Ellerhorst, J; Eton, O; Papadopoulos, N; Plager, C; Smith, T | 1 |
| Brandwijk, RJ; Dings, RP; Griffioen, AW; Thijssen, VL | 1 |
| Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG | 1 |
| Baguley, BC; Basse, B; Joseph, WR; Marshall, ES; van Brunt, B; Wake, G; Wall, DJ | 1 |
| Azzabi, A; Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Hughes, AN; Kelly, C; Lind, MJ; Maraveyas, A; Plummer, ER; Todd, R | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Albertini, MR; Dietrich, L; Eastman, M; Kim, K; King, DM; Kwak, M; Schalch, H; Walker, L | 1 |
| Creagan, ET; Croghan, GA; Holtan, SG; Ingle, JN; Kaur, JS; Kottschade, LA; Markovic, SN; Pitot, HC; Rao, RD | 1 |
| Becker, S; Brix, G; Dellian, M; Eichhorn, ME; Griebel, J; Jauch, KW; Michaelis, U; Ruhstorfer, H; Sauer, B; Strieth, S; Teifel, M; Werner, A | 1 |
| Agarwala, S; Argiris, A; Bergsland, E; Rugo, H; Wanebo, HJ | 1 |
| Chiba, N; Hanada, M; Ishioka, C; Kakudo, Y; Kato, S; Noguchi, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T | 1 |
| Anichini, A; Ballatore, C; Felding-Habermann, B; Janda, KD; Kaufmann, GF; Kim, Y; Lillo, AM; Liu, Y; Mortarini, R; Steiniger, SC; Zhou, B | 1 |
| Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| Baeuerle, PA; Clark, D; Freimark, B; Nickel, J; Pernasetti, F; Van Epps, D | 1 |
| Ferrara, KW; LaBell, R; Lum, AF; Matsunaga, TO; McCallan, J; Stieger, SM; Tartis, MS | 1 |
| Collichio, FA; Dees, EC; Goldberg, RM; Hawkins, MJ; Ivanova, A; Lindley, C; Mu, H; O'Neil, BH; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
| Aristu, J; Garrán, C; González Cao, M; Martín Algarra, S; Nieto, Y; Ponz, M; Viteri, S | 1 |
| Bartlett, DL; Brown, CK; Demarco, RA; Dong, Xda E; Ito, N; Lotze, MT; Popovic, P; Shand, SH; Watkins, S; Winikoff, S; Zeh, HJ | 1 |
| Clement, MV; Lee, SC; Pervaiz, S; Sim, N; Yadav, SK | 1 |
| Haikel, Y; Hassan, M; Hengge, UR; Selimovic, D | 1 |
| Tuma, RS | 1 |
| Bissery, MC; Dykes, DJ; Harrison, SD; Waud, WR | 1 |
| Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I | 1 |
| Aamdal, S; Franklin, HR; Kaplan, S; Kerger, J; Paridaens, R; Schachter, J; Verweij, J; Wanders, J; Wolff, I | 1 |
| DeLisa, AF; Gregory, RE | 1 |
| Lakshmi, MS; Parker, C; Piura, B; Sherbet, GV | 1 |
| Einzig, AI; Wiernik, PH | 1 |
| Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR | 1 |
| Battafarano, DF; Burris, HA; Keeling, JH; Older, SA; Zimmerman, GC | 1 |
| Mackenzie, H; Mohith, A; Retsas, S | 1 |
| Mohith, A; Photiou, A; Retsas, S | 1 |
| Hájek, R; Slavik, M; Vorlicek, J | 1 |
| Hunter, NR; Inoue, T; Kim, EE; Li, C; Milas, L; Wallace, S; Yang, DJ; Yu, D | 1 |
| Coatsworth, S; Einzig, AI; Recio, A; Rodriquez, R; Schuchter, LM; Wiernik, PH | 1 |
| Leong, LK; Moss, J; Photiou, A; Retsas, S; Shah, P | 1 |
| Bujor, L; Caffau, C; Favaro, D; Gobitti, C; Quaia, M; Robieux, I; Santarosa, M; Spada, A; Trovò, MG; Zanelli, GD | 1 |
| Banerjee, S; Brown, DL; Fallis, AG | 1 |
| Bhuyan, BK; Lopes, NM; Miller, HP; Young, ND | 1 |
| Benson, LT; Einzig, AI; Kaplan, J; Tan, V; Tentoramano, L; Wadler, S; Wiernik, PH | 1 |
| Bernard, S; Brouwer, KL; Gonzalez, P; Lawrence, P; Letrent, SP; Mudd, PN; Radomski, KM; Socinski, MA; Steagall, A | 1 |
| Orel, NF | 1 |
| Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
| Bohling, CA; Forrest, LJ; Hershey, AE; Imondi, AR; Kurzman, ID; Placke, ME; Stonerook, M; Vail, DM | 1 |
| Berd, D; Mastrangelo, MJ; Nathan, FE; Sato, T | 1 |
| Bani, MR; Ben-David, Y; Chu, W; Kapoor, M; Kerbel, RS; Lu, SJ; Pak, BJ; Tamir, A | 1 |
| Constantinides, PP; Kessler, D; Lalji, S; Lambert, KJ; Ma, W; Quay, SC; Schneider, B; Tustian, AK; Wentzel, B; Worah, D | 1 |
| Chen, ZJ; Hopper, E; Murphy, M; Shen, H; Tew, KD; Zilfou, JT | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Feun, LG; Hurley, J; Marini, A; Savaraj, N | 1 |
| Clark, J; Finkelstein, DM; Haluska, FG; Hodi, FS; Soiffer, RJ | 1 |
| Cohen, SM | 1 |
| Dutcher, JP; Einzig, AI; Garowski, E; Hochster, H; Sasloff, J; Smith, TJ; Trump, DL; Wiernik, PH | 1 |
| Einzig, AI; Schwartz, EL; Wiernik, PH | 1 |
| Glover, DJ | 1 |
| Benjamin, RS; Legha, SS; Papadopoulos, N; Raber, M; Ring, S | 1 |
| Baker, JR; Donehower, RC; Gralla, RJ; Leyland-Jones, B; Ohnuma, T; Trump, DL; Van Echo, DA; Von Hoff, DD; Weiss, RB; Wiernik, PH | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
| Dutcher, JP; Einzig, A; Lipton, RB; Schwartz, EL; Strauman, JJ; Wiernik, PH | 1 |
| Berger, A; Böcker, A; Burkard, M; Busch, C; Donaubauer, K; Frank, J; Garbe, C; Lauer, UM; Leischner, C; Niessner, H; Riepl, H; Sinnberg, T; Urmann, C; Venturelli, S | 1 |
17 review(s) available for paclitaxel and Melanoma
| Article | Year |
|---|---|
Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Topics: Albumins; Angiogenesis Inhibitors; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferons; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Tumor Microenvironment | 2022 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimumab; Melanoma; Paclitaxel; Sulfonamides; Temozolomide; Vemurafenib | 2018 |
Efficacy of nab-paclitaxel in treating metastatic melanoma.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Temozolomide | 2019 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Nab-paclitaxel in patients with metastatic melanoma.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Skin Neoplasms | 2015 |
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine | 2011 |
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Topics: Albumins; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2013 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide | 2002 |
Metastatic melanoma: chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide | 2002 |
Targeting growth factors and angiogenesis; using small molecules in malignancy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Genes, ras; Humans; Melanoma; Nanostructures; Neoplasms; Paclitaxel; Proto-Oncogene Proteins B-raf; Receptors, Growth Factor; Signal Transduction | 2006 |
Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins | 1993 |
Taxol in malignant melanoma.
Topics: Clinical Trials as Topic; Humans; Melanoma; Paclitaxel | 1993 |
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Melanoma; Microtubules; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Paclitaxel | 1996 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
Taxol: a new agent active in melanoma and ovarian cancer.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Melanoma; Microtubules; Ovarian Neoplasms; Paclitaxel | 1991 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
68 trial(s) available for paclitaxel and Melanoma
| Article | Year |
|---|---|
Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors | 2020 |
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mucous Membrane; Paclitaxel; Prognosis; Survival Rate | 2021 |
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides | 2021 |
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B-Lymphocytes; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Insulin-Like Growth Factor I; Lymphocytes, Tumor-Infiltrating; Melanoma; Paclitaxel; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, Fibroblast Growth Factor, Type 3; Skin Neoplasms; Tumor Microenvironment | 2017 |
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Everolimus; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf | 2018 |
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Pyrimidines; Sulfonamides | 2018 |
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Indazoles; Male; Melanoma; Middle Aged; Mutation; Paclitaxel; Prognosis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Survival Rate | 2019 |
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Paclitaxel; Sirolimus; Skin Neoplasms; Treatment Outcome | 2013 |
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Health Status; Humans; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quality of Life; Surveys and Questionnaires | 2014 |
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Skin Neoplasms; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2014 |
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate | 2014 |
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Pyridones; Pyrimidinones; Skin Neoplasms | 2015 |
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2015 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CTLA-4 Antigen; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf | 2015 |
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Dideoxynucleosides; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiography; Treatment Outcome | 2015 |
Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult | 2015 |
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome | 2016 |
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult | 2015 |
An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Drug Administration Schedule; Female; Humans; Indazoles; Infusions, Intravenous; Male; Melanoma; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome; Up-Regulation | 2016 |
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Topics: Antineoplastic Agents; Dacarbazine; Disease Progression; Drug Substitution; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Survival Analysis | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult | 2016 |
Targeting Both Tumor and Stroma Cells to Treat Melanoma: NIPAWILMA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Skin Neoplasms; Stromal Cells; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
Topics: Adult; Aged; Cancer Vaccines; Carboplatin; Dendritic Cells; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Peptide Fragments; Pilot Projects; Skin Neoplasms | 2017 |
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Prospective Studies; Skin Neoplasms; Treatment Outcome | 2008 |
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome | 2009 |
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Treatment Outcome; Young Adult | 2009 |
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Exanthema; Fatigue; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Pain; Skin Neoplasms; Survival Rate; Tumor Burden | 2009 |
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Humans; Hydrazines; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2009 |
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms | 2010 |
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Pyrazoles; Skin Neoplasms; Sulfonamides | 2010 |
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Life Expectancy; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Patient Selection; Stilbenes | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2011 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Uveal Neoplasms | 2010 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide | 2011 |
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms | 2011 |
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2012 |
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Placebos; Proportional Hazards Models; Treatment Outcome | 2012 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2013 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms | 2012 |
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib | 2013 |
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
Topics: Antineoplastic Agents, Phytogenic; Disease-Free Survival; Double-Blind Method; Humans; Hydrazines; L-Lactate Dehydrogenase; Melanoma; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2013 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Male; Melanoma; Paclitaxel; Time Factors; Treatment Outcome | 2003 |
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Choroid Neoplasms; Disease Progression; Female; Humans; Injections, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins | 2005 |
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Temozolomide | 2005 |
Phase II trial of weekly paclitaxel in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Survival Rate | 2005 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Paclitaxel | 2007 |
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids | 1995 |
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids | 1995 |
Taxol and vinorelbine: a new active combination for disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 1996 |
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1996 |
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel | 1998 |
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Time Factors | 1998 |
Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Mucous Membrane; Paclitaxel; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2000 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2002 |
Phase II study of paclitaxel and carboplatin for malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel | 2002 |
A phase II study of taxol in patients with malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Paclitaxel | 1991 |
Taxol: a new agent active in melanoma and ovarian cancer.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Melanoma; Microtubules; Ovarian Neoplasms; Paclitaxel | 1991 |
171 other study(ies) available for paclitaxel and Melanoma
| Article | Year |
|---|---|
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
Topics: Allantois; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biopolymers; Cattle; Chorion; Drug Screening Assays, Antitumor; G2 Phase; GTP Phosphohydrolases; Humans; In Vitro Techniques; Indoles; Melanoma; Mice; Mice, Nude; Mitosis; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured | 2001 |
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
Topics: Animals; Biological Factors; Colonic Neoplasms; Diosgenin; Disease Models, Animal; Diterpenes; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 3-Ring; HL-60 Cells; Humans; Inhibitory Concentration 50; KB Cells; Leukemia P388; Male; Melanoma; Mice; Molecular Structure; Naphthoquinones; Ovarian Neoplasms; Paclitaxel; Polymers; Prostatic Neoplasms; Triterpenes; Tumor Cells, Cultured | 2002 |
Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents.
Topics: Cell Line; Humans; Melanoma; Oligopeptides; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin Modulators | 2004 |
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imidazoles; Male; Melanoma; Models, Molecular; Paclitaxel; Prostatic Neoplasms; Structure-Activity Relationship; Tubulin Modulators | 2012 |
Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum.
Topics: Animals; Antineoplastic Agents; Ascomycota; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease Models, Animal; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Piperazines | 2014 |
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
Topics: Animals; Apoptosis; Binding Sites; Colchicine; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Heterografts; Humans; Male; Melanoma; Polymerization; Prostatic Neoplasms; Pyrimidines; Tubulin | 2018 |
Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Heterografts; Humans; Hydroxyquinolines; Indoles; Inhibitor of Apoptosis Proteins; Melanoma; Mice; Pyrrolidines; Structure-Activity Relationship; Survivin | 2018 |
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
Topics: Animals; Cell Proliferation; Chalcones; Humans; Male; Melanoma; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Conformation; Tubulin; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
A Novel Anticancer Stem Cell Compound Derived from Pleuromutilin Induced Necroptosis of Melanoma Cells.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diterpenes; Humans; Melanoma; Mice; Mice, Nude; Microbial Sensitivity Tests; Necroptosis; Neoplastic Stem Cells; Pleuromutilins; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab-resistant acral and mucosal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms | 2022 |
Cancer microcell initiation and determination.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Nucleus; Cell Self Renewal; Cell Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Endosomal Sorting Complexes Required for Transport; Female; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Indicators and Reagents; Melanoma; Microscopy, Electron; NADP; Neoplasm Recurrence, Local; Neoplasms; Neutral Red; Paclitaxel; Stress, Physiological; Time-Lapse Imaging; Transcription Factors; Transfection; Uterine Cervical Neoplasms | 2021 |
Serotonin type-3 receptor antagonists selectively kill melanoma cells through classical apoptosis, microtubule depolymerisation, ERK activation, and NF-κB downregulation.
Topics: Antiemetics; Apoptosis; Down-Regulation; Humans; Melanoma; Molecular Docking Simulation; NF-kappa B; Ondansetron; Paclitaxel; Serotonin; Tropisetron; Vomiting | 2023 |
Exosomes are secreted at similar densities by M21 and PC3 human cancer cells and show paclitaxel solubility.
Topics: Cell Line, Tumor; Drug Carriers; Extracellular Vesicles; Humans; Male; Melanoma; Microscopy, Electron, Transmission; Paclitaxel; Prostatic Neoplasms; Solubility | 2022 |
ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Phosphatidylserines; Skin Neoplasms; Tumor Microenvironment | 2022 |
Myrsinane-type diterpenes from Euphorbia gedrosiaca with cell growth inhibitory activity and apoptotic effects on melanoma cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Chromatography, Liquid; Diterpenes; Euphorbia; Flow Cytometry; Growth Inhibitors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Paclitaxel; Plant Extracts | 2022 |
The mechanisms of immune-chemotherapy with nanocomplex codelivery of pTRP-2 and adjuvant of paclitaxel against melanoma.
Topics: Adjuvants, Immunologic; Animals; Humans; Melanoma; Mice; NF-kappa B; Paclitaxel; Toll-Like Receptor 4 | 2021 |
Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis.
Topics: Animals; Cell Line, Tumor; Cell Movement; Chemokine CCL21; Ligands; Lymphatic Metastasis; Melanoma; Mice; Paclitaxel; Receptors, CCR7 | 2022 |
Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers.
Topics: Biomimetics; Cell Line, Tumor; Drug Delivery Systems; Erythrocytes; Humans; Melanoma; Nanoparticles; Paclitaxel; Phosphatidylethanolamines; Polymers; Tumor Microenvironment | 2022 |
An injectable thermosensitive hydrogel/nanomicelles composite for local chemo-immunotherapy in mouse model of melanoma.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hydrogels; Immunotherapy; Melanoma; Mice; Micelles; Paclitaxel; Poloxamer | 2022 |
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment | 2022 |
Simultaneous chemotherapy/sonodynamic therapy of the melanoma cancer cells using a gold-paclitaxel nanostructure.
Topics: Cell Line, Tumor; Gold; Humans; Melanoma; Metal Nanoparticles; Nanoparticles; Paclitaxel; Photochemotherapy | 2022 |
B16F10 Cell Membrane-Based Nanovesicles for Melanoma Therapy Are Superior to Hyaluronic Acid-Modified Nanocarriers.
Topics: Cell Line, Tumor; Cell Membrane; Humans; Hyaluronic Acid; Melanoma; Nanoparticles; Paclitaxel; Phospholipids; Polyethylene Glycols | 2022 |
pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Cell Line, Tumor; Colchicine; Humans; Hydrogen-Ion Concentration; Lung; Lung Neoplasms; Melanoma; Mice; Nanomedicine; Paclitaxel; Polymers; Schiff Bases; Tubulin Modulators; Vincristine | 2022 |
Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
Topics: Antineoplastic Agents; Betulinic Acid; Cell Line; Docetaxel; Humans; In Vitro Techniques; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Pentacyclic Triterpenes; Skin Neoplasms; Taxoids | 2022 |
Synergetic effect of high dose rate radiations (10× FFF/2400 MU/min/10 MV x-rays) and paclitaxel selectively eliminates melanoma cells.
Topics: Apoptosis; Humans; Melanoma; Paclitaxel; X-Rays | 2023 |
Cocoa presents cytotoxicity against melanoma cancer cell lines (A-375 e B16-F10) and improves chemotherapy activity by increasing oxidative stress.
Topics: Antineoplastic Agents; Cacao; Cell Line, Tumor; Melanoma; Oxidative Stress; Paclitaxel | 2022 |
Modification of α-Tocopherol Succinate with a Tumor-targeting Peptide Conjugate Enhances the Antitumor Efficacy of a Paclitaxel-loaded Lipid Aggregate.
Topics: alpha-Tocopherol; Animals; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Lipids; Melanoma; Mice; Paclitaxel; Peptides | 2023 |
Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Flavonoids; Humans; Melanoma; Mice; Paclitaxel | 2022 |
SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Colchicine; Humans; Male; Melanoma; Mice; Paclitaxel; Polymerization; Tubulin; Tubulin Modulators | 2023 |
Multifunctional Modified Tumor Cell Membranes-Coated Adjuvant PTX against Melanoma.
Topics: Cell Line, Tumor; Cell Membrane; Drug Carriers; Humans; Melanoma; Paclitaxel | 2023 |
In situ administration of temperature-sensitive hydrogel composite loading paclitaxel microspheres and cisplatin for the treatment of melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cisplatin; Hydrogels; Melanoma; Mice; Microspheres; Paclitaxel; Temperature | 2023 |
Development of Nanocarrier-Based Radionuclide and Photothermal Therapy in Combination with Chemotherapy in Melanoma Cancer Treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gold; Humans; Melanoma; Nanotubes; Paclitaxel; Phototherapy; Photothermal Therapy; Radioisotopes | 2023 |
Topical Cream Carrying Drug-Loaded Nanogels for Melanoma Treatment.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Humans; Melanoma; Mice; Micelles; Nanogels; Paclitaxel; Polyethylene Glycols | 2023 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Mitoxantrone; Paclitaxel; Vemurafenib | 2023 |
Synthesis and characterization of dual light/temperature-responsive supramolecular injectable hydrogel based on host-guest interaction between azobenzene and starch-grafted β-cyclodextrin: Melanoma therapy with paclitaxel.
Topics: beta-Cyclodextrins; Humans; Hydrogels; Melanoma; Paclitaxel; Polymers; Temperature | 2023 |
Talin2 and KANK2 functionally interact to regulate microtubule dynamics, paclitaxel sensitivity and cell migration in the MDA-MB-435S melanoma cell line.
Topics: Actins; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cytoskeletal Proteins; Humans; Integrins; Melanoma; Microtubules; Paclitaxel; Protein Isoforms; Talin | 2023 |
Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms; Syndrome | 2023 |
Measuring Melanoma Nanomechanical Properties in Relation to Metastatic Ability and Anti-Cancer Drug Treatment Using Scanning Ion Conductance Microscopy.
Topics: Actins; Antineoplastic Agents; Cisplatin; Dacarbazine; Humans; Melanoma; Microscopy, Atomic Force; Paclitaxel | 2023 |
Antitumour effects of Liporaxel (oral paclitaxel) for canine melanoma in a mouse xenograft model.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Dogs; Female; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel | 2020 |
SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Multidrug Resistance-Associated Proteins; Paclitaxel; Side-Population Cells; SOXB1 Transcription Factors; Transcriptional Activation | 2020 |
Low-dose paclitaxel via hyaluronan-functionalized bovine serum albumin nanoparticulate assembly for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cations; Cell Movement; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Hyaluronic Acid; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms, Experimental; Paclitaxel; Particle Size; Serum Albumin, Bovine; Surface Properties; Tumor Cells, Cultured | 2020 |
Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.
Topics: Apoptosis; Cell Line, Tumor; Humans; Liposomes; Melanoma; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Microenvironment | 2020 |
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Female; Humans; Infusions, Intra-Arterial; Melanoma; Middle Aged; Paclitaxel; Patient Safety; Rectal Neoplasms; Temozolomide; Treatment Outcome | 2020 |
Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
Topics: Aged; CD8-Positive T-Lymphocytes; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Melanoma; Middle Aged; Myeloid-Derived Suppressor Cells; Paclitaxel; Pilot Projects; Skin Neoplasms; Tumor Microenvironment | 2021 |
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Melanoma; Metformin; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms | 2021 |
ATR Inhibitors and Paclitaxel in Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Humans; Melanoma; Paclitaxel; Protein Kinase Inhibitors | 2021 |
Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Humans; Immune Checkpoint Inhibitors; Melanoma; Paclitaxel; Retrospective Studies; Skin Neoplasms | 2022 |
Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAF
Topics: Animals; Cell Line, Tumor; Flavonoids; Humans; Melanoma; Mice; Mitogen-Activated Protein Kinase Kinases; Nanoparticles; Paclitaxel; Particle Size; Proto-Oncogene Proteins B-raf | 2021 |
Fattigation-platform theranostic nanoparticles for cancer therapy.
Topics: Animals; Cell Line, Tumor; Coated Materials, Biocompatible; Gelatin; Magnetite Nanoparticles; Melanoma; Mice; Neoplasms, Experimental; Oleic Acid; Paclitaxel; Silicon Dioxide; Theranostic Nanomedicine | 2017 |
DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.
Topics: AC133 Antigen; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice, Inbred BALB C; MicroRNAs; Neoplastic Stem Cells; Paclitaxel; SOXB1 Transcription Factors; Xenograft Model Antitumor Assays | 2017 |
Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Ceramides; Drug Carriers; Emulsions; Melanoma; Nanoparticles; Paclitaxel; Skin; Skin Absorption; Swine; Triglycerides | 2017 |
Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
Topics: Acetates; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Interleukin-6; Interleukin-8; Melanoma; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Tumor Microenvironment; Tyramine | 2018 |
Combined Action of PGRPs-Hsp70 Cytotoxic Complex with Paclitaxel Improves Outcomes of Melanoma Treatment in Mice.
Topics: Animals; Antineoplastic Agents; HSP70 Heat-Shock Proteins; Kaplan-Meier Estimate; Melanoma; Mice; Mice, Inbred DBA; Paclitaxel; Recombinant Proteins | 2018 |
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; CD8-Positive T-Lymphocytes; CX3C Chemokine Receptor 1; Cytotoxins; Drug Therapy, Combination; Female; Granzymes; Humans; Immunotherapy; Male; Melanoma; Mice; Neoplasms; Paclitaxel; Perforin; Programmed Cell Death 1 Receptor | 2018 |
Temporary suppression the sequestrated function of host macrophages for better nanoparticles tumor delivery.
Topics: Animals; Antineoplastic Agents; Biological Availability; Clodronic Acid; Drug Carriers; Lactic Acid; Liposomes; Liver; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tissue Distribution | 2018 |
Complete Response of Metastatic Melanoma to Second Line Chemotherapy with Paclitaxel and Carboplatin - Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Melanoma; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome | 2018 |
Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line; Humans; Hydroxychloroquine; Integrin alphaVbeta3; Liposomes; Lung Neoplasms; Melanoma; Mice, Inbred C57BL; Neuropilin-1; Oligopeptides; Paclitaxel; Paxillin; Phosphatidylethanolamines; Polyethylene Glycols; Receptors, CXCR4 | 2018 |
A robust control system for targeting melanoma by a supermolecular DDMC/paclitaxel complex.
Topics: Allosteric Site; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DEAE-Dextran; Female; Humans; Kinetics; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Paclitaxel; Particle Size; Signal Transduction; Tumor Microenvironment; Zalcitabine | 2018 |
Enhanced Transdermal Drug Delivery by Transfersome-Embedded Oligopeptide Hydrogel for Topical Chemotherapy of Melanoma.
Topics: Administration, Topical; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell-Penetrating Peptides; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hydrogels; Melanoma; Mice; Mice, Nude; Oligopeptides; Paclitaxel; Skin Neoplasms | 2018 |
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; Humans; Melanoma; Paclitaxel; Protein Kinase Inhibitors; Retrospective Studies; Tumor Protein p73; Tumor Suppressor Protein p53 | 2018 |
Retinoic acid increases the anticancer effect of paclitaxel by inducing differentiation of cancer stem cells in melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Neoplastic Stem Cells; Paclitaxel; SOXB1 Transcription Factors; Tretinoin | 2018 |
The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor; Retrospective Studies | 2019 |
Targeting the MAPK pathway in advanced BRAF wild-type melanoma.
Topics: Humans; Indazoles; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides | 2019 |
A sinister black finding in the stomach.
Topics: Acrylonitrile; Aged; Aniline Compounds; Barrett Esophagus; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma; Mutation; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach; Tomography, X-Ray Computed; Tubulin Modulators; Uveal Neoplasms | 2019 |
In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms | 2019 |
miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy.
Topics: Aged; Animals; Apoptosis; Calcium-Binding Proteins; Carcinogenesis; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Membrane Proteins; Mice; MicroRNAs; Middle Aged; Paclitaxel; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2019 |
Evaluating the Anti-cancer Efficacy of a Synthetic Curcumin Analog on Human Melanoma Cells and Its Interaction with Standard Chemotherapeutics.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Curcumin; Dose-Response Relationship, Drug; Drug Interactions; Humans; Melanoma; Mitochondria; Molecular Structure; Oxidative Stress; Paclitaxel; Tamoxifen | 2019 |
Intravenous administration of manuka honey inhibits tumor growth and improves host survival when used in combination with chemotherapy in a melanoma mouse model.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Honey; Humans; Leptospermum; Male; Melanoma; Mice; Necrosis; Paclitaxel; Tumor Burden | 2013 |
Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vulvar Neoplasms | 2013 |
BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Biphenyl Compounds; Caspase 9; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Melanoma; Nitrophenols; Paclitaxel; Piperazines; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Spindle Apparatus; Sulfonamides; Tubulin | 2013 |
[Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Melanoma; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tyrphostins | 2013 |
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calibration; Female; Humans; Mass Spectrometry; Melanoma; Mice; Mice, Nude; Nanoparticles; Paclitaxel | 2013 |
Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Caspases; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel | 2013 |
Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.
Topics: AC133 Antigen; Antigens, CD; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Transfer Techniques; Glycoproteins; Humans; Immunohistochemistry; Melanoma; Neoplasm Metastasis; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Peptides | 2014 |
Multifunctional biodegradable polymer nanoparticles with uniform sizes: generation and in vitro anti-melanoma activity.
Topics: Biocompatible Materials; Biodegradation, Environmental; Cell Death; Cell Line, Tumor; Cell Survival; Endocytosis; Humans; Inhibitory Concentration 50; Lactic Acid; Light; Magnetic Resonance Imaging; Magnetite Nanoparticles; Melanoma; Microscopy, Fluorescence; Paclitaxel; Particle Size; Phantoms, Imaging; Polyesters; Polymers; Polyvinyl Alcohol; Quantum Dots; Scattering, Radiation | 2013 |
Overexpression of Heat Shock Transcription Factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Silencing; Heat Shock Transcription Factors; Humans; Inhibitory Concentration 50; Melanoma; Melanoma, Experimental; Mice; Mutation; Paclitaxel; Transcription Factors | 2013 |
Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Skin Neoplasms; Treatment Failure | 2013 |
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carboplatin; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Melanoma; Molecular Targeted Therapy; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Skin Neoplasms; Spheroids, Cellular; Tumor Stem Cell Assay | 2014 |
Combination of Cl‑IB‑MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR‑dependent autophagy and mitotic catastrophe on human melanoma cells.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Blotting, Western; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Fluorescent Antibody Technique; Humans; Melanoma; Mitosis; Paclitaxel; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2014 |
Case of advanced melanoma who died from meningitis carcinomatosa after carboplatin and paclitaxel with good response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Carcinomatosis; Middle Aged; Paclitaxel; Positron-Emission Tomography | 2014 |
Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Kaplan-Meier Estimate; Linoleic Acids, Conjugated; Liposomes; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Oligopeptides; Paclitaxel; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
Topics: Adenosine; Animals; Antineoplastic Agents; Cell Physiological Phenomena; Disease Progression; Drug Screening Assays, Antitumor; Humans; Inosine; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Receptor, Adenosine A3; Tumor Cells, Cultured | 2014 |
Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Lansoprazole; Melanoma; Mice; Mice, SCID; Paclitaxel; Proton Pump Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Non-occlusive mesenteric ischemia after chemotherapy for metastatic melanoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Humans; Intestines; Ischemia; Melanoma; Paclitaxel; Splanchnic Circulation | 2015 |
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Topics: Albumins; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Movement; Cell Nucleus Shape; Cell Proliferation; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Extracellular Space; Humans; Lactic Acid; Melanoma; Mitosis; Necrosis; Neoplasm Metastasis; Organophosphates; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines | 2015 |
Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Melanoma; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins B-raf; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Vemurafenib | 2015 |
Salvage chemotherapy with weekly paclitaxel for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib | 2015 |
Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lipids; Melanoma; Mice; Nanoparticles; Neoplastic Stem Cells; Paclitaxel | 2015 |
Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mitosis; Mutation, Missense; Paclitaxel; Proto-Oncogene Proteins B-raf; Sulfonamides; Transcriptional Activation | 2015 |
Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Indoles; Melanoma; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols; Polymers; Surface Properties | 2015 |
PEGylated graphene oxide for tumor-targeted delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Graphite; Melanoma; Mice; Mice, Inbred C57BL; Oxides; Paclitaxel; Polyethylene Glycols; Rats, Wistar | 2015 |
Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
Topics: Biological Transport; Cell Line, Tumor; Cell-Penetrating Peptides; Doxorubicin; Drug Delivery Systems; Humans; Ligands; Liposomes; Melanoma; Paclitaxel; Peptides; Transferrin; Xenograft Model Antitumor Assays | 2016 |
In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Integrin alphaVbeta3; Melanoma; Mice; Micelles; Microscopy, Confocal; Oligopeptides; Paclitaxel | 2015 |
Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?
Topics: Albumins; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mutation, Missense; Paclitaxel; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2015 |
Is chemotherapy still an option in the treatment of melanoma?
Topics: Albumins; Dacarbazine; Female; Humans; Male; Melanoma; Paclitaxel; Skin Neoplasms | 2015 |
Versatile antitumor potential of isoxanthohumol: Enhancement of paclitaxel activity in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Flavonoids; Humans; MAP Kinase Signaling System; Melanoma; Mice, Inbred C57BL; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Xanthones | 2016 |
Multiwalled Carbon Nanotubes Inhibit Tumor Progression in a Mouse Model.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Melanoma; Mice; Nanotubes, Carbon; Neoplasms, Experimental; Paclitaxel | 2016 |
Nanoparticle-dendrimer hybrid nanocapsules for therapeutic delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dendrimers; Female; Gold; Melanoma; Mice; Mice, Inbred C57BL; Nanocapsules; Nanoparticles; Paclitaxel; Thiocarbamates | 2016 |
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.
Topics: Adult; Aged; Biomarkers, Pharmacological; Carboplatin; Cell-Free Nucleic Acids; DNA, Neoplasm; Exome Sequencing; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Paclitaxel; Precision Medicine; Proto-Oncogene Proteins c-kit; Vaginal Neoplasms | 2016 |
Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Survival; Endostatins; Female; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Recombinant Proteins; Xenograft Model Antitumor Assays | 2016 |
A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Galactosylceramides; Immunotherapy; Liposomes; Melanoma; Mice, Inbred C57BL; Nanostructures; Paclitaxel; Treatment Outcome | 2016 |
Paclitaxel-induced aberrant mitosis and mitotic slippage efficiently lead to proliferative death irrespective of canonical apoptosis and p53.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Clone Cells; Cysteine; DNA; Genes, Reporter; HeLa Cells; Humans; Kinesins; Melanoma; Mitochondrial Membranes; Mitosis; Paclitaxel; Permeability; Phenotype; Reproducibility of Results; Time-Lapse Imaging; Tumor Suppressor Protein p53 | 2016 |
Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Sulfonamides; Ubiquitin-Protein Ligases; Vemurafenib | 2017 |
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Ipilimumab; Markov Chains; Melanoma; Models, Economic; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance.
Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Melanoma; Nanoparticles; Paclitaxel; Particle Size; Polymers; Structure-Activity Relationship; Surface Properties; Tumor Cells, Cultured | 2017 |
Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indoles; Melanoma; Multidrug Resistance-Associated Protein 2; Paclitaxel; Receptors, Somatotropin; Sulfonamides; Vemurafenib | 2017 |
Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Delivery Systems; Endocytosis; Glucose-6-Phosphate Isomerase; HCT116 Cells; HT29 Cells; Humans; Melanoma; Membrane Microdomains; Mice; Neoplasms; Paclitaxel; Receptors, Autocrine Motility Factor; Receptors, Cytokine; Ubiquitin-Protein Ligases | 2008 |
Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ceramides; Humans; Lysophosphatidylcholines; Lysophospholipids; Melanoma; Membrane Potential, Mitochondrial; Multienzyme Complexes; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Pyrophosphatases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromatin; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Histones; Humans; Immunohistochemistry; Melanoma; Models, Biological; Paclitaxel; Tubulin | 2009 |
Studies on paclitaxel-loaded glyceryl monostearate nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Glycerides; Lipids; Melanoma; Nanoparticles; Paclitaxel; Particle Size | 2009 |
Efficacy of poly(sebacic acid-co-ricinoleic acid) biodegradable delivery system for intratumoral delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line; Decanoic Acids; Drug Carriers; Drug Delivery Systems; Female; Humans; Materials Testing; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Paclitaxel; Polymers; Ricinoleic Acids; Survival Rate | 2010 |
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
Topics: Adenosine Triphosphate; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluoresceins; Humans; Melanoma; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2009 |
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Delivery Systems; Female; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Protein Kinases; Signal Transduction; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases | 2009 |
MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Division; Cell Survival; DNA Replication; DNA, Neoplasm; Down-Regulation; G2 Phase; Humans; Melanoma; Mitosis; Paclitaxel; Proto-Oncogene Proteins c-myc; Spindle Apparatus; Tumor Cells, Cultured | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Acute gout during treatment with paclitaxel for metastatic melanoma.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Gout; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms | 2009 |
Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.
Topics: Animals; Carbocyanines; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Endocytosis; Endothelial Cells; Flow Cytometry; Fluorescent Dyes; Humans; Integrins; Melanoma; Mice; Micelles; Microscopy, Confocal; Paclitaxel; Particle Size; Peptides, Cyclic; Polyethylene Glycols; Polyglactin 910 | 2011 |
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Regression of paclitaxel-induced maculopathy with oral acetazolamide.
Topics: Acetazolamide; Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbonic Anhydrase Inhibitors; Female; Humans; Lymphatic Metastasis; Macular Edema; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Tomography, Optical Coherence; Vision Disorders; Visual Acuity | 2012 |
Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Topics: Animals; CD8-Positive T-Lymphocytes; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Immunosuppression Therapy; Inflammation; Melanoma; Mice; Mice, Knockout; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-ret; Purines; Receptors, Antigen, T-Cell; Sildenafil Citrate; Sulfones; Tumor Microenvironment; ZAP-70 Protein-Tyrosine Kinase | 2012 |
Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Cytokines; Daunorubicin; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione; Humans; Isoxazoles; Melanoma; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survival Analysis; Xenograft Model Antitumor Assays | 2012 |
Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Immunotherapy; Lipopolysaccharides; Melanoma; Mice; Mice, Inbred C57BL; Paclitaxel | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flavonoids; Flow Cytometry; Humans; Interleukin-8; Melanoma; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Vascular Endothelial Growth Factor A | 2012 |
Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to α(v)β₃ integrin overexpressing tumors.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fatty Acids; Humans; Integrin alphaVbeta3; Melanoma; Micelles; Oligopeptides; Paclitaxel; Surface-Active Agents | 2012 |
Croton lechleri sap and isolated alkaloid taspine exhibit inhibition against human melanoma SK23 and colon cancer HT29 cell lines.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Croton; HT29 Cells; Humans; Melanoma; Paclitaxel; Plant Extracts; Vinblastine | 2012 |
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calgranulin B; Chronic Disease; Dose-Response Relationship, Immunologic; Humans; Immunosuppression Therapy; Inflammation; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinases; Myeloid Cells; Paclitaxel; Primary Cell Culture; Skin Neoplasms; Spleen; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2013 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunophenotyping; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Melanoma; Microscopy, Electron; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Temozolomide; Time Factors; Tumor Cells, Cultured; Vindesine | 2002 |
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Capillaries; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Division; Cells, Cultured; Chemotaxis; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelium, Vascular; Fibrosarcoma; Glioblastoma; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2003 |
Tumor growth retardation, cure, and induction of antitumor immunity in B16 melanoma-bearing mice by low electric field-enhanced chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Cell Division; Cisplatin; Combined Modality Therapy; Electric Stimulation Therapy; Macrophages; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Spleen; T-Lymphocytes; Time Factors | 2003 |
Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Chemokine CXCL1; Chemokines; Chemokines, CXC; Chemotactic Factors; Dactinomycin; Enzyme Inhibitors; Female; Gene Expression Profiling; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Nitriles; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel | 2003 |
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine.
Topics: Antineoplastic Agents; Cell Cycle; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Keratinocytes; Melanoma; Paclitaxel; Purinergic P1 Receptor Antagonists; Pyrimidines; Receptor, Adenosine A3; Triazoles; Tumor Cells, Cultured; Vindesine | 2003 |
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Base Sequence; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Molecular Sequence Data; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Transplantation, Heterologous | 2004 |
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Flow Cytometry; Humans; Mathematics; Melanoma; Models, Biological; Paclitaxel | 2004 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Capsules; Contrast Media; Cricetinae; Gadolinium DTPA; Lipids; Magnetic Resonance Imaging; Melanoma; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 2006 |
[A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Humans; Kidney Neoplasms; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Paclitaxel; Quality of Life | 2006 |
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.
Topics: Amino Acid Sequence; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Ligands; Melanoma; Molecular Chaperones; Molecular Sequence Data; Paclitaxel; Peptide Library; Peptides, Cyclic; Protein Transport | 2006 |
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Cell Growth Processes; Chick Embryo; Collagen Type IV; Dose-Response Relationship, Immunologic; Drug Synergism; Epitopes; Extracellular Matrix; Female; Humans; Immunoglobulin G; Immunoglobulin M; Male; Melanoma; Mice; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1 | 2006 |
Therapeutic effects of paclitaxel-containing ultrasound contrast agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Death; Chick Embryo; Chorioallantoic Membrane; Contrast Media; Drug Carriers; Drug Delivery Systems; Humans; Integrin alphaVbeta3; Ligands; Melanoma; Microbubbles; Neoplasm Proteins; Paclitaxel; Sonication; Tumor Cells, Cultured | 2006 |
Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Paclitaxel; Remission Induction; Skin Neoplasms | 2007 |
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; Combined Modality Therapy; HMGB1 Protein; Humans; Immunotherapy; Killer Cells, Lymphokine-Activated; Melanoma; Melphalan; Microscopy, Confocal; Necrosis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2007 |
Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27: a functional proteomic analysis.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Electrophoresis, Gel, Two-Dimensional; Genes, Dominant; Heat-Shock Proteins; Humans; Melanoma; Mitochondria; Paclitaxel; Peptides; Proteomics; rac1 GTP-Binding Protein; Sensitivity and Specificity; Tumor Cells, Cultured; Up-Regulation | 2007 |
Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Down-Regulation; Enzyme Activation; Free Radical Scavengers; Humans; Ion Channels; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; MAP Kinase Signaling System; Melanoma; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Proteins; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Reactive Oxygen Species; Uncoupling Protein 2 | 2008 |
Reactive oxygen species may have antitumor activity in metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Hydrazines; Melanoma; Paclitaxel; Randomized Controlled Trials as Topic; Reactive Oxygen Species; Research Design; Skin Neoplasms | 2008 |
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drugs, Investigational; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids; Transplantation, Heterologous | 1995 |
Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma.
Topics: Calcium-Binding Proteins; Cell Cycle; Gene Expression; Melanocyte-Stimulating Hormones; Melanoma; Neoplasm Metastasis; Paclitaxel; S100 Proteins; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1994 |
Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases.
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Edema; Female; Humans; Leg; Leiomyosarcoma; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Scleroderma, Localized; Taxoids | 1995 |
The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Drug Screening Assays, Antitumor; Humans; Melanoma; Paclitaxel; Tumor Cells, Cultured | 1996 |
Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug.
Topics: Animals; Drug Screening Assays, Antitumor; Female; Mammary Neoplasms, Experimental; Melanoma; Mice; Paclitaxel; Polyethylene Glycols; Prodrugs; Tumor Cells, Cultured | 1996 |
In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Fluorescent Antibody Technique, Indirect; Humans; Melanoma; Microscopy, Electron; Paclitaxel; Tubulin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1997 |
Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations.
Topics: Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Melanoma; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
Differential effects of taxol on two human cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescent Antibody Technique, Indirect; HT29 Cells; Humans; Melanoma; Microtubules; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 1997 |
Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Cattle; Cells, Cultured; Dimethyl Sulfoxide; Docetaxel; Drug Screening Assays, Antitumor; In Vitro Techniques; Melanoma; Mice; Microtubule-Associated Proteins; Mitosis; Paclitaxel; Taxoids | 1997 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |
Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Dog Diseases; Dogs; Doxorubicin; Female; Lung Neoplasms; Male; Melanoma; Paclitaxel; Sarcoma | 1999 |
Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Cisplatin; Humans; Intramolecular Oxidoreductases; Melanoma; Methotrexate; Paclitaxel; Tumor Cells, Cultured | 2000 |
Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Emulsions; Female; Filtration; Humans; Melanoma; Mice; Mice, Inbred Strains; Paclitaxel; Particle Size; Serum Albumin; Skin Neoplasms; Solubility; Sterilization; Survival Analysis; Vitamin E | 2000 |
Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoprotection; Electrophoresis, Polyacrylamide Gel; Fibroblasts; HeLa Cells; Humans; Melanoma; Mercaptoethylamines; Mice; NF-kappa B; NF-kappa B p50 Subunit; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-mdm2; Transcription Factor AP-1; Transcription Factors; Transcriptional Activation; Tumor Suppressor Protein p53 | 2001 |
Chemotherapy of metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Humans; Melanoma; Mitolactol; Paclitaxel | 1992 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
A phase II trial of taxol in metastatic melanoma.
Topics: Adult; Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1990 |
Hypersensitivity reactions from taxol.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Colonic Neoplasms; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Immediate; Leukemia, Myeloid, Acute; Male; Melanoma; Middle Aged; Paclitaxel; Premedication | 1990 |
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Humans; Infusions, Intravenous; Kinetics; Melanoma; Neoplasms; Nervous System Diseases; Neutropenia; Paclitaxel | 1987 |
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.
Topics: Acetylation; Apoptosis; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavanones; Flavonoids; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Humulus; Melanoma; Molecular Docking Simulation; Protein Isoforms; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases | 2018 |